Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance
radiation response. This study will test the combination of Sorafenib™ and radiation therapy
with or without temozolomide to determine tolerance of the combined treatments. Defining safe
dosing of Sorafenib™ in this combination therapy will be achieved.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University